Status:
COMPLETED
Effect of Methylphenidate on Ecologic Function in Paediatric Acquired Brain Injury Population
Lead Sponsor:
Loewenstein Hospital
Conditions:
Acquired Brain Injury
Eligibility:
All Genders
4-18 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate the influence of Methylphenidate in pediatric acquired brain injury population, regarding ecologic (every day) function. It is hypothesized that the functio...
Detailed Description
Attention deficits in patients with acquired brain injury (ABI) are one of the most common cognitive disorders acquainted. Prevalence of attention deficits after cerebrovascular accident (CVA) varies ...
Eligibility Criteria
Inclusion
- Male and female.
- Ages 4-18 years old.
- No contraindications for Methylphenidate treatment such as hypersensitivity, cardiac disturbances unbalanced seizures etc'.
- Informed consent given by their legal guardian.
- Acquired brain injury
Exclusion
- Refusal to participate by either guardian or child.
- No attentional disturbances in a computed screening exam: "TOVA".
- Medical contraindications to treatment with Methylphenidate such as short QT syndrome.
- Side effects due to treatment with Methylphenidate.
- Under medical treatment of medications enhancing dopamine/ noradrenaline release such as Amantadine.
- Unable to participate in tasks planned due to severe motor or cognitive disabilities.
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT02227056
Start Date
January 1 2014
End Date
March 1 2017
Last Update
February 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Loewenstein Rehabilitation Hospital Center
Raanana, Israel, 43100